Clinical trials have demonstrated that combining PD-1/PD-L1 inhibitors with angiogenesis inhibitors as the first-line treatment for advanced HCC and RCC significantly improves the OS and PFS and using PD-L1 inhibitor atezolizumab with RAF-MEK inhibitors (vemurafenib plus cobimetinib) in patients with BRAFV600-mutant metastatic melanoma has a longer clinical remission [47,50,60,61,95]. The gene discussed is MAP2K7; the disease is renal cell carcinoma.